In The Press June 21, 2020

Nick Mitrokostas Discusses New Biosimilar Approval and the Outlook for 2020 (The Center For Biosimilars)

In this episode of Not So Different podcast Nick Mitrokostas, an Intellectual Property (IP) lawyer and partner in Goodwin's IP Litigation group, discusses how the approval of Pfizer’s pegfilgrastim biosimilar (Nyvepria) will affect the biosimilar market and what he sees for the rest of 2020. Listen to The Center For Biosimilars’ podcast here